<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03441178</url>
  </required_header>
  <id_info>
    <org_study_id>ENG-17-001</org_study_id>
    <nct_id>NCT03441178</nct_id>
  </id_info>
  <brief_title>A Prospective, Multi-Center Evaluation of the ENSEAL X1 Large Jaw Tissue Sealer</brief_title>
  <official_title>A Prospective, Multi-Center Evaluation of the ENSEAL X1 Large Jaw Tissue Sealer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ethicon Endo-Surgery</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ethicon Endo-Surgery</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, single-arm, multi-center, evaluation will collect clinical data in a&#xD;
      post-market setting. The three types of procedures studied will be colectomy, gynecological,&#xD;
      and thoracic. Investigators will perform each procedure using the device in compliance with&#xD;
      their standard surgical approach and the ENSEAL X1 instructions for use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to prospectively generate device specific clinical&#xD;
      data related to hemostasis in a post-market setting using the ENSEAL X1 per its instructions&#xD;
      for use. There will be no blinding or planned interim analysis in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2018</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Vessels Where Hemostasis (&lt;= Grade 3) is Achieved Using ENSEAL X1</measure>
    <time_frame>Intraoperative, after vessel has been transected</time_frame>
    <description>Grade 1: no bleeding at transection site;&#xD;
Grade 2: minor bleeding at transection site, no intervention needed;&#xD;
Grade 3: minor bleeding at transection site, mild intervention needed, use of monopolar device and/or touch-ups with ENSEAL X1;&#xD;
Grade 4: significant bleeding (e.g., pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or ligation with additional hemostatic products (e.g., hemoclips, staples, sutures, fibrin sealants, other advanced energy products).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemostasis Grading Assessment for Each Vessel Transection</measure>
    <time_frame>Intraoperative, after vessel has been transected</time_frame>
    <description>Grade 1: no bleeding at transection site;&#xD;
Grade 2: minor bleeding at transection site, no intervention needed;&#xD;
Grade 3: minor bleeding at transection site, mild intervention needed, use of monopolar device and/or touch-ups with ENSEAL X1;&#xD;
Grade 4: significant bleeding (e.g., pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or ligation with additional hemostatic products (e.g., hemoclips, staples, sutures, fibrin sealants, other advanced energy products).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Grade 3 Vessels Needing ENSEAL X1 Touch-up</measure>
    <time_frame>Intraoperative, after vessel has been transected</time_frame>
    <description>Grade 1: no bleeding at transection site;&#xD;
Grade 2: minor bleeding at transection site, no intervention needed;&#xD;
Grade 3: minor bleeding at transection site, mild intervention needed, use of monopolar device and/or touch-ups with ENSEAL X1;&#xD;
Grade 4: significant bleeding (e.g., pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or ligation with additional hemostatic products (e.g., hemoclips, staples, sutures, fibrin sealants, other advanced energy products).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hemostasis Grade 4 Transections and Hemostatic Interventions Used</measure>
    <time_frame>Intraoperative, after vessel has been transected</time_frame>
    <description>Grade 1: no bleeding at transection site;&#xD;
Grade 2: minor bleeding at transection site, no intervention needed;&#xD;
Grade 3: minor bleeding at transection site, mild intervention needed, use of monopolar device and/or touch-ups with ENSEAL X1;&#xD;
Grade 4: significant bleeding (e.g., pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or ligation with additional hemostatic products (e.g., hemoclips, staples, sutures, fibrin sealants, other advanced energy products).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Colectomy; Gynecological; Thoracic</condition>
  <arm_group>
    <arm_group_label>Colectomy/Gynecological/Thoracic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Any colectomy/gynecological/thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ENSEAL X1</intervention_name>
    <description>ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
    <arm_group_label>Colectomy/Gynecological/Thoracic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Elective procedure (colectomy, gynecological, or thoracic) where at least one vessel&#xD;
             is planned to be transected by the ENSEAL X1 device per its instructions for use;&#xD;
&#xD;
          2. Willingness to give consent and comply with all study-related evaluations and&#xD;
             treatment schedule; and&#xD;
&#xD;
          3. At least 18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Physical or psychological condition which would impair study participation; or&#xD;
&#xD;
          2. Enrollment in a concurrent clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Robb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital</name>
      <address>
        <city>Yeovil</city>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 15, 2018</study_first_submitted>
  <study_first_submitted_qc>February 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <results_first_submitted>July 22, 2020</results_first_submitted>
  <results_first_submitted_qc>August 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT03441178/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT03441178/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Planned on 100 enrolled but 101 was enrolled due to timing and study closure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Colectomy</title>
          <description>Any thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
        </group>
        <group group_id="P2">
          <title>Gynecological</title>
          <description>Any gynecological procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
        </group>
        <group group_id="P3">
          <title>Thoracic</title>
          <description>Any thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ENSEAL X1 Large Jaw Tissue Sealer</title>
          <description>Use of the ENSEAL X1 Large Jaw Tissue Sealer</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.8" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Vessels Where Hemostasis (&lt;= Grade 3) is Achieved Using ENSEAL X1</title>
        <description>Grade 1: no bleeding at transection site;&#xD;
Grade 2: minor bleeding at transection site, no intervention needed;&#xD;
Grade 3: minor bleeding at transection site, mild intervention needed, use of monopolar device and/or touch-ups with ENSEAL X1;&#xD;
Grade 4: significant bleeding (e.g., pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or ligation with additional hemostatic products (e.g., hemoclips, staples, sutures, fibrin sealants, other advanced energy products).</description>
        <time_frame>Intraoperative, after vessel has been transected</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colectomy</title>
            <description>Any thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
          </group>
          <group group_id="O2">
            <title>Gynecological</title>
            <description>Any gynecological procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
          </group>
          <group group_id="O3">
            <title>Thoracic</title>
            <description>Any thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
          </group>
          <group group_id="O4">
            <title>Total</title>
            <description>Any colectomy, gynecological or thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Vessels Where Hemostasis (&lt;= Grade 3) is Achieved Using ENSEAL X1</title>
          <description>Grade 1: no bleeding at transection site;&#xD;
Grade 2: minor bleeding at transection site, no intervention needed;&#xD;
Grade 3: minor bleeding at transection site, mild intervention needed, use of monopolar device and/or touch-ups with ENSEAL X1;&#xD;
Grade 4: significant bleeding (e.g., pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or ligation with additional hemostatic products (e.g., hemoclips, staples, sutures, fibrin sealants, other advanced energy products).</description>
          <units>Percentage of Vessels</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Vessels Transected</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Vessels Transected</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="94.2" lower_limit="89.3" upper_limit="97.3"/>
                    <measurement group_id="O3" value="96.7" lower_limit="90.6" upper_limit="99.3"/>
                    <measurement group_id="O4" value="96.2" lower_limit="93.4" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemostasis Grading Assessment for Each Vessel Transection</title>
        <description>Grade 1: no bleeding at transection site;&#xD;
Grade 2: minor bleeding at transection site, no intervention needed;&#xD;
Grade 3: minor bleeding at transection site, mild intervention needed, use of monopolar device and/or touch-ups with ENSEAL X1;&#xD;
Grade 4: significant bleeding (e.g., pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or ligation with additional hemostatic products (e.g., hemoclips, staples, sutures, fibrin sealants, other advanced energy products).</description>
        <time_frame>Intraoperative, after vessel has been transected</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colectomy</title>
            <description>Any thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
          </group>
          <group group_id="O2">
            <title>Gynecological</title>
            <description>Any gynecological procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
          </group>
          <group group_id="O3">
            <title>Thoracic</title>
            <description>Any thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
          </group>
          <group group_id="O4">
            <title>Total</title>
            <description>Any colectomy, gynecological or thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemostasis Grading Assessment for Each Vessel Transection</title>
          <description>Grade 1: no bleeding at transection site;&#xD;
Grade 2: minor bleeding at transection site, no intervention needed;&#xD;
Grade 3: minor bleeding at transection site, mild intervention needed, use of monopolar device and/or touch-ups with ENSEAL X1;&#xD;
Grade 4: significant bleeding (e.g., pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or ligation with additional hemostatic products (e.g., hemoclips, staples, sutures, fibrin sealants, other advanced energy products).</description>
          <units>Vessels Transected</units>
          <param>Count of Units</param>
          <units_analyzed>Vessels Transected</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Vessels Transected</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Grade 3 Vessels Needing ENSEAL X1 Touch-up</title>
        <description>Grade 1: no bleeding at transection site;&#xD;
Grade 2: minor bleeding at transection site, no intervention needed;&#xD;
Grade 3: minor bleeding at transection site, mild intervention needed, use of monopolar device and/or touch-ups with ENSEAL X1;&#xD;
Grade 4: significant bleeding (e.g., pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or ligation with additional hemostatic products (e.g., hemoclips, staples, sutures, fibrin sealants, other advanced energy products).</description>
        <time_frame>Intraoperative, after vessel has been transected</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colectomy</title>
            <description>Any thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
          </group>
          <group group_id="O2">
            <title>Gynecological</title>
            <description>Any gynecological procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
          </group>
          <group group_id="O3">
            <title>Thoracic</title>
            <description>Any thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
          </group>
          <group group_id="O4">
            <title>Total</title>
            <description>Any colectomy, gynecological or thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Grade 3 Vessels Needing ENSEAL X1 Touch-up</title>
          <description>Grade 1: no bleeding at transection site;&#xD;
Grade 2: minor bleeding at transection site, no intervention needed;&#xD;
Grade 3: minor bleeding at transection site, mild intervention needed, use of monopolar device and/or touch-ups with ENSEAL X1;&#xD;
Grade 4: significant bleeding (e.g., pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or ligation with additional hemostatic products (e.g., hemoclips, staples, sutures, fibrin sealants, other advanced energy products).</description>
          <units>Vessels Transected</units>
          <param>Number</param>
          <units_analyzed>Grade 3 Vessels</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Grade 3 Vessels</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hemostasis Grade 4 Transections and Hemostatic Interventions Used</title>
        <description>Grade 1: no bleeding at transection site;&#xD;
Grade 2: minor bleeding at transection site, no intervention needed;&#xD;
Grade 3: minor bleeding at transection site, mild intervention needed, use of monopolar device and/or touch-ups with ENSEAL X1;&#xD;
Grade 4: significant bleeding (e.g., pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or ligation with additional hemostatic products (e.g., hemoclips, staples, sutures, fibrin sealants, other advanced energy products).</description>
        <time_frame>Intraoperative, after vessel has been transected</time_frame>
        <population>There were no Grade 4 vessels seen in the colectomy procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Gynecological</title>
            <description>Any gynecological procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
          </group>
          <group group_id="O2">
            <title>Thoracic</title>
            <description>Any thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Any colectomy, gynecological or thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hemostasis Grade 4 Transections and Hemostatic Interventions Used</title>
          <description>Grade 1: no bleeding at transection site;&#xD;
Grade 2: minor bleeding at transection site, no intervention needed;&#xD;
Grade 3: minor bleeding at transection site, mild intervention needed, use of monopolar device and/or touch-ups with ENSEAL X1;&#xD;
Grade 4: significant bleeding (e.g., pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or ligation with additional hemostatic products (e.g., hemoclips, staples, sutures, fibrin sealants, other advanced energy products).</description>
          <population>There were no Grade 4 vessels seen in the colectomy procedures.</population>
          <units>Vessels Transected</units>
          <param>Number</param>
          <units_analyzed>Grade 4 Vessels</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Grade 4 Vessels</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left uterine artery and vein (suture)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left uterine artery (suture)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right uterine artery (suture)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right ovarian artery (suture)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Short gastric (suture -1; hemoclip -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastroepiploic (suture)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 Weeks Post Procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ENSEAL X1 Large Jaw Tissue Sealer</title>
          <description>Use of the ENSEAL X1 Large Jaw Tissue Sealer</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Suture related complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Procedural vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jason Waggoner, PhD</name_or_title>
      <organization>Ethicon Endo-Surgery</organization>
      <phone>+1 513.337.8310</phone>
      <email>jwaggon1@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

